Getting Out the Gout

An underdiagnosed condition gets its first new drug in 40 years.

CLINICAL RESEARCH
Search results for “CLINICAL RESEARCH”
Close

Where Psychedelic Research Goes Next
A new generation of research looks at psilocybin, LSD and other mind-altering drugs. Both the challenges and the therapeutic promise are enormous.

One Man’s Poison
New genetic sequencing technologies have opened the door to animal venom therapies.

The Tender Years
Adversity in early childhood too often equals poor health later. Now researchers are looking for ways to change the equation.
See More
FDA
Search results for “FDA”
Close

What Is a Collaborative Community?
An unconventional new model makes industry meetups a key part of medical device regulation.

No COVID-19 Tests? Let Us Make One
With tests in short supply, some hospitals are creating homegrown versions in their own labs. The pandemic may prove how essential such efforts are.

What Comes After Transvaginal Mesh?
Prolapse of the pelvic organs is uncomfortable and widespread, and its treatments are sometimes dangerous. But new approaches are on the way.
See More
OBESITY
Search results for “OBESITY”
Close

Prescription: Thin
Weight loss strategies have always put diet and exercise center stage. Can two new drugs change the medical mindset about obesity?

Fathers-to-Be, Take Note
A wave of research shows how a pregnancy can be put at risk by drinking, diet and exposures to toxins—on the part of the male.

Seeing Past the Scale
Obesity expert Fatima Cody Stanford looks at how physician bias around weight causes harm to patients.
See More

Published On January 15, 2010

AN AILMENT THAT USUALLY STRIKES DURING AGES of opulence now afflicts 5.1 million Americans. The return of gout, which is caused by uric acid crystallizing in the joints, is linked with the obesity epidemic. The overweight produce too much uric acid and don’t excrete it well. Though gout has been around for millennia, the condition is still often underdiagnosed and mismanaged—more’s the pity, now that the FDA has approved Uloric (febuxostat), the first new gout drug in 40 years, which lowers uric acid more effectively than previous treatments.

Back
to top